Comparison of commercial lateral flow immunoassays and ELISA for SARS-CoV-2 antibody detection

Autor: Nuria Tormo Palop, Maria Martínez Serrano, Concepción Gimeno Cardona, David Navalpotro Rodríguez, Mª Dolores Ocete Mochón, Marta Moreno Córdoba, Roberto Olmos Arenas
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
0301 basic medicine
diagnosis
specificity
Antibodies
Viral
Immunoglobulin G
Serology
COVID-19 Testing
0302 clinical medicine
antibody detection
Medicine
030212 general & internal medicine
Child
Aged
80 and over
Immunoassay
medicine.diagnostic_test
biology
Middle Aged
Infectious Diseases
Female
Antibody
Coronavirus Infections
Antibody detection
Adult
Adolescent
Coronavirus disease 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Pneumonia
Viral
030106 microbiology
Enzyme-Linked Immunosorbent Assay
Sensitivity and Specificity
Article
Betacoronavirus
Young Adult
03 medical and health sciences
Virology
Humans
Serologic Tests
Pandemics
Aged
Clinical Laboratory Techniques
business.industry
SARS-CoV-2
COVID-19
Serum samples
sensitivity
Immunoglobulin A
biology.protein
business
Zdroj: Journal of Clinical Virology
ISSN: 1873-5967
1386-6532
Popis: Highlights • Serological tests showed poor performances in early serum samples but improved in days 8-15 after onset of symptoms • IgM band in LFI had low sensitivities and might be inadequate for acute diagnosis of COVID-19 infection • Euroimmun commercial IgA ELISA was more sensitive but less specificic than IgG, which showed 100% specificity • Ten days after symptoms’ onset, critical and severe COVID-19 patients had higher ELISA IgG ratios than asymptomatic or mild ones
Background COVID-19 pandemic has spread worldwide since December 2019. Serological tests for SARS-CoV-2 antibody testing are needed for detection of current or past infections. A wide range of commercial tests is available. However, most of them need to be validated. Study design The aim was to compare a commercial IgG and IgA ELISA (Euroimmun) with three lateral flow immunoassays (LFI): Hangzhou Alltest Biotech, Wuhan UNscience Biotechnology and Guangzhou Wondfo Biotech. Specificity was calculated with 62 available serum samples from 2018/19. The study included 152 sera from patients of which 109 were RT-PCR positive. Sensitivities for ELISA anti SARS-CoV-2 IgG and IgA were 81,5% and 93,1% and specificities 100% and 80,6%, respectively. LFI showed variable performances, overall results being better for Guangzhou Wondfo Biotech. Conclusions Commercial serological tests are useful for detection of antibodies in patients with COVID-19. ELISA presented better results than LFI. The results allowed to incorporate the most sensitive LFI to the daily workflow, combining with ELISA. Careful validation is encouraged before clinical laboratories start using these tests.
Databáze: OpenAIRE
Externí odkaz: